| abstract |
PROBLEM TO BE SOLVED: To provide a drug for treating hematologic cancer, particularly human acute myeloid leukemia (AML). To treat hematologic cancer, the SIRPα-CD47 interaction is regulated, and a composition for that purpose is provided. In some embodiments, a method for treating hematologic cancer, preferably human acute myeloid leukemia, and the use of SIRPα polypeptides, fragments and fusion proteins for that purpose are provided. [Selection diagram] None |